TY - JOUR
T1 - Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia
AU - Potvin, Stéphane
AU - Stip, Emmanuel
AU - Lipp, Olivier
AU - Roy, Marc André
AU - Demers, Marie France
AU - Bouchard, Roch Hugo
AU - Gendron, Alain
N1 - Funding Information:
The authors wish to dedicate this work to Dr Jean-Yves Roy, a pioneer psychiatrist in Quebec who passed away before the completion of this trial. The study—an Investigator Initiated Trial—was supported by Astra-Zeneca Pharmaceuticals. E.S. is holder of the Eli Lilly Chair of Schizophrenia from the University of Montreal. S.P. is holder of a postdoctoral scholarship from the Fonds de Recherche en Santé du Québec.
PY - 2008/1
Y1 - 2008/1
N2 - The current study sought to identify the variables, derived from the self-medication hypothesis, which predicted substance abuse evolution during a homogeneous 3-month antipsychotic treatment. Twenty-four patients were diagnosed with schizophrenia and substance abuse (mainly cannabis and alcohol). Substance abuse, psychiatric symptoms, anhedonia, and social adjustment were assessed at baseline and study endpoint. Linear regression analyses were performed. Better social adaptation and worse anhedonia predicted substance abuse improvements. Conversely, greater psychoactive substance (PAS) use predicted endpoint positive and depressive symptoms. These results suggest that: (i) substance abuse interferes with psychiatric prognosis in schizophrenia; and (ii) dual diagnosis treatments leading patients to engage in alternative social activities may render substance abuse less appealing. Further studies are warranted to dissociate the causes and consequences of substance abuse in schizophrenia.
AB - The current study sought to identify the variables, derived from the self-medication hypothesis, which predicted substance abuse evolution during a homogeneous 3-month antipsychotic treatment. Twenty-four patients were diagnosed with schizophrenia and substance abuse (mainly cannabis and alcohol). Substance abuse, psychiatric symptoms, anhedonia, and social adjustment were assessed at baseline and study endpoint. Linear regression analyses were performed. Better social adaptation and worse anhedonia predicted substance abuse improvements. Conversely, greater psychoactive substance (PAS) use predicted endpoint positive and depressive symptoms. These results suggest that: (i) substance abuse interferes with psychiatric prognosis in schizophrenia; and (ii) dual diagnosis treatments leading patients to engage in alternative social activities may render substance abuse less appealing. Further studies are warranted to dissociate the causes and consequences of substance abuse in schizophrenia.
KW - Anhedonia
KW - Schizophrenia
KW - Social adaptation
KW - Substance use disorders
UR - http://www.scopus.com/inward/record.url?scp=37649004411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37649004411&partnerID=8YFLogxK
U2 - 10.1080/00952990701764631
DO - 10.1080/00952990701764631
M3 - Article
C2 - 18161645
AN - SCOPUS:37649004411
SN - 0095-2990
VL - 34
SP - 75
EP - 82
JO - American Journal of Drug and Alcohol Abuse
JF - American Journal of Drug and Alcohol Abuse
IS - 1
ER -